ClinicalTrials.gg
RecruitingNCT06990035Updated Oct 27, 2026

Implementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With Depression

An interventional study of Mediterranean diet lessons program and Physical activity in Major Depressive Disorder (MDD), sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Recruiting at 2 sites in Italy. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 27, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Depressive Disorder, Major with a site in Italy — 16 open to participants now, 18 under way, 6 of them phase 3. Depressive Disorder, Major · Italy.

Planned enrollment
28th of 39
120 · median 348
Started
2026
with 3 others
No phase
6 of 50
4 open now
Primary completion
2027-08
later than 11 of 17 live
Registered
42nd of 50
by date
Lead sponsor
3 of 50
IRCCS Centro San Giovanni di Dio Fatebenefratelli

Among the 50 studies in Depressive Disorder, Major with a site in Italy, this one is the 28th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 42nd registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

16 of the 50 studies in Depressive Disorder, Major with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Depressive Disorder, Major with a site in Italy, or all of them as a file.
02

Study summary

This clinical trial aims to investigate whether an integrative approach combining education on the Mediterranean diet and physical activity (PA) can significantly reduce depressive symptomatology in individuals with major depressive disorder. The study will evaluate changes in depressive symptoms and assess biological modulations, including alterations in the gut microbiota and inflammatory markers, resulting from the PA intervention.

Participants will be randomized into two arms: the active control group will attend a series of lessons focused on the Mediterranean diet, while the experimental group will participate in the same dietary lessons combined with a structured PA program of 12 weeks.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major depressive disorder
  • Physical activity
  • Mediterranean Diet
  • Microbiome
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of depression ( criteria, American Psychiatric Association 2013).
  • Depressive symptoms assessed using MADR, BDI, or ZDR scales.
  • Ability to provide written .
  • Self-reported moderate-intensity leisure physical activity of less than 150 minutes per week.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe psychopathology.
  • Medical to physical activity.
  • Orthopedic problems or other conditions limiting physical fitness assessment or currently pregnant.
  • Patients who underwent antibiotic/anti-inflammatory treatments in the last 3 months
  • Active gastrointestinal diseases
  • and/or chronic inflammatory disorders
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Mediterranean diet lessons program

    Behavioral: Mediterranean diet lessons program

  • Experimental
    Experimental Group

    Physical activity program

    Behavioral: Mediterranean diet lessons program · Behavioral: Physical activity

Interventions

  • BehavioralMediterranean diet lessons program

    Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.

  • BehavioralPhysical activity

    Participants will undergo a 12-week physical exercise program guided by specified personal trainers.

06

What researchers measure

Primary outcomes

  1. MADR Scale for Depression

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered scale designed to assess the severity of depressive symptoms. It consists of 10 items, each rated on a scale from 0 to 6, yielding a total score ranging from 0 to 60. Higher scores indicate greater severity of depression, meaning a worse clinical outcome.

    Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

  2. Beck Depression Inventory - II

    The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the presence and severity of depressive symptoms. It comprises 21 items, each rated on a scale from 0 to 3, resulting in a total score ranging from 0 to 63. Higher scores reflect more severe depressive symptoms, indicating a worse clinical outcome.

    Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

  3. Zung Self-Rating Depression Scale

    The Zung Self-Rating Depression Scale (ZRS) is a self-administered questionnaire designed to assess the level of depressive symptoms in individuals. It consists of 20 items, each rated on a scale from 1 to 4, based on how often symptoms are experienced. The raw total score ranges from 20 to 80, which is often converted to an index score (ranging from 25 to 100) by multiplying the raw score by 1.25. Higher scores indicate more severe depression

    Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

  4. Personal and Social Performance Scale

    The Personal and Social Performance Scale (PSP) is a clinician-rated instrument used to assess personal and social functioning in individuals with mental disorders. The total score ranges from 1 to 100, with higher scores indicating better functioning and a more favorable clinical outcome.

    Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

  5. World Health Organization Quality of Life - Bref

    The WHOQOL-BREF is a self-report questionnaire developed by the WHO to assess quality of life across multiple domains. It contains 26 items rated on a 5-point Likert scale. Higher scores indicate a better quality of life, reflecting a more favorable outcome.

    Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

Secondary outcomes

  1. Immunitary-related factors levels

    Plasma/serum levels of cytokines

    Time frame: Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).

  2. Gut Microbiome Composition

    Time frame: Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).

07

Study locations

2 of 2 sites recruiting
  • IRCCS Centro San Giovanni fi Dio Fatebenefratelli
    Brescia, Italy 25125, Italy
    Recruiting
  • Comunità Fraternità società cooperativa sociale ONLUS
    Ospitaletto, Italy 25035, Italy
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 19 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jul 2025 → Jan 2026, primary completion Feb 2026 → Aug 2027 and completion Feb 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 25, 2025
StartActual
Jan 26, 2026was Jul 2025
Primary completionEst.
Aug 2027was Feb 2026
CompletionEst.
Aug 2027was Feb 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Italy)
  • IRCCS Centro San Giovanni fi Dio Fatebenefratelli · Brescia, Italy
  • Comunità Fraternità società cooperativa sociale ONLUS · Ospitaletto, Italy
Show 1 removed
  • IRCCS Centro San Giovanni fi Dio Fatebenefratelli · Brescia, Italy
Oct 27, 2026
Start date
Jul 2025→Jan 26, 2026 (actual)
Oct 27, 2026
Primary completion
Feb 2026→Aug 2027
Oct 27, 2026
Study completion
Feb 2026→Aug 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    2 sites added, 1 site removed
    Show 2 added (2 Italy)
    • IRCCS Centro San Giovanni fi Dio Fatebenefratelli · Brescia, Italy
    • Comunità Fraternità società cooperativa sociale ONLUS · Ospitaletto, Italy
    Show 1 removed
    • IRCCS Centro San Giovanni fi Dio Fatebenefratelli · Brescia, Italy
    Start date Jul 2025→Jan 26, 2026 (now actual)
    Primary completion Feb 2026→Aug 2027
    Study completion Feb 2026→Aug 2027
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06990035
Lead sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Collaborators
Comunità Fraternità società cooperativa sociale ONLUS
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jan 26, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Annamaria Cattaneo, PhD
Contact
acattaneo@fatebenefratelli.eu
0039 030 3501599

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion